Yahoo
NasdaqCM - Nasdaq Real Time Price USD

GeoVax Labs, Inc. (GOVX)

0.6382 -0.0037 (-0.58%)
As of 9:52:05 AM EDT. Market Open.
Chart Range Bar
Loading chart for GOVX
  • Previous Close 0.6419
  • Open 0.6300
  • Bid 0.4500 x 200
  • Ask 2.5500 x 100
  • Day's Range 0.6300 - 0.6500
  • 52 Week Range 0.5900 - 19.8000
  • Volume 113,092
  • Avg. Volume 756,561
  • Market Cap (intraday) 3.325M
  • Beta (5Y Monthly) 3.66
  • PE Ratio (TTM) --
  • EPS (TTM) -5.6200
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 10.00

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

www.geovax.com

19

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/26/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GOVX
85.07%
S&P 500 (^GSPC)
12.18%

1-Year Return

GOVX
96.74%
S&P 500 (^GSPC)
18.76%

3-Year Return

GOVX
99.70%
S&P 500 (^GSPC)
74.30%

5-Year Return

GOVX
99.97%
S&P 500 (^GSPC)
71.79%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -4.43M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

10.00
10.00 Average
0.6382 Current
10.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/16/2026
Analyst D. Boral Capital
Rating Action Maintains
Rating Hold
Price Action Maintains
Price Target 1 -> 1

Statistics

View More

Valuation Measures

Annual
As of 8/25/2026
  • Market Cap

    3.34M

  • Enterprise Value

    520.15k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.11

  • Price/Book (mrq)

    1.90

  • Enterprise Value/Revenue

    3.28

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -256.80%

  • Return on Equity (ttm)

    -891.59%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -20.43M

  • Diluted EPS (ttm)

    -5.6200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.14M

  • Total Debt/Equity (mrq)

    18.35%

  • Levered Free Cash Flow (ttm)

    -10.82M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.6382 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: